FibroGen (FGEN) News Today $0.35 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period FY2024 EPS Estimates for FibroGen Raised by William BlairNovember 18 at 2:09 AM | americanbankingnews.comFibroGen (NASDAQ:FGEN) Stock, Option ChainNovember 15, 2024 | benzinga.comStockNews.com Begins Coverage on FibroGen (NASDAQ:FGEN)November 14, 2024 | americanbankingnews.comFibroGen Reports Strong Q3 Growth and Future PlansNovember 13, 2024 | markets.businessinsider.comFibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost ReductionsNovember 13, 2024 | finance.yahoo.comFibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call TranscriptNovember 12, 2024 | seekingalpha.comFibroGen Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | globenewswire.comFibroGen to Report Third Quarter 2024 Financial ResultsNovember 4, 2024 | globenewswire.comDisc Medicine appoints Kaushik as Chief Technical OfficerOctober 23, 2024 | markets.businessinsider.comFibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ShiftsOctober 9, 2024 | finance.yahoo.comFibroGen to exit Mission Bay lease earlyOctober 4, 2024 | bizjournals.comFibroGen announces executive departures amid cost cutsSeptember 11, 2024 | uk.investing.comFGEN Sep 2024 2.500 callSeptember 8, 2024 | ca.finance.yahoo.comFibroGen to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | markets.businessinsider.comFibroGen, Inc. (NASDAQ:FGEN) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesAugust 9, 2024 | finance.yahoo.comFibroGen Inc.: Sell Rating Maintained Amid Uncertainties and Limited Upside PotentialAugust 8, 2024 | markets.businessinsider.comSan Francisco biotech company FibroGen guts staff after failed cancer trialsAugust 7, 2024 | msn.comFibroGen Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 6, 2024 | markets.businessinsider.comFGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q2 2024August 6, 2024 | investorplace.comOne Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment ProgramJuly 31, 2024 | benzinga.comS.F. biotech company to cut 75% of staff after clinical trial failuresJuly 31, 2024 | bizjournals.comFibroGen Layoffs 2024: What to Know About the Latest FGEN Job CutsJuly 31, 2024 | investorplace.comWhy Is FibroGen (FGEN) Stock Down 44% Today?July 31, 2024 | investorplace.comFibroGen to Cut U.S. Workforce by 75% on Termination of Pancreatic Cancer Pamrevlumab ProgramJuly 31, 2024 | marketwatch.comFibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate UpdateJuly 31, 2024 | finance.yahoo.comFibroGen stock plunges 48% post-market on failed drug studiesJuly 31, 2024 | msn.comFibroGen to Report Second Quarter 2024 Financial ResultsJuly 30, 2024 | globenewswire.comFibroGen, Inc. (NASDAQ:FGEN) is a favorite amongst institutional investors who own 54%July 29, 2024 | finance.yahoo.comFibroGen Target of Unusually High Options Trading (NASDAQ:FGEN)FibroGen, Inc. (NASDAQ:FGEN - Get Free Report) saw unusually large options trading on Monday. Stock traders bought 3,658 call options on the stock. This represents an increase of approximately 117% compared to the average daily volume of 1,686 call options.July 8, 2024 | marketbeat.comFibroGen, Inc. (NASDAQ:FGEN) Sees Significant Increase in Short InterestFibroGen, Inc. (NASDAQ:FGEN - Get Free Report) was the recipient of a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 8,090,000 shares, an increase of 8.4% from the May 31st total of 7,460,000 shares. Based on an average trading volume of 2,320,000 shares, the days-to-cover ratio is presently 3.5 days.July 2, 2024 | marketbeat.comFibroGen, Inc. (NASDAQ:FGEN) Insider Deyaa Adib Buys 22,123 SharesJune 14, 2024 | insidertrades.comFibroGen, Inc. (NASDAQ:FGEN) Insider Purchases $25,883.91 in StockFibroGen, Inc. (NASDAQ:FGEN - Get Free Report) insider Deyaa Adib purchased 22,123 shares of the company's stock in a transaction dated Wednesday, June 12th. The stock was bought at an average cost of $1.17 per share, for a total transaction of $25,883.91. Following the completion of the transaction, the insider now owns 82,123 shares in the company, valued at $96,083.91. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.June 13, 2024 | marketbeat.comPennant Investors LP Makes New $681,000 Investment in FibroGen, Inc. (NASDAQ:FGEN)Pennant Investors LP acquired a new position in FibroGen, Inc. (NASDAQ:FGEN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 768,400 shares of the biopharmaceutical company'sJune 11, 2024 | marketbeat.comFibroGen, Inc. (NASDAQ:FGEN) Shares Acquired by Armistice Capital LLCArmistice Capital LLC grew its stake in FibroGen, Inc. (NASDAQ:FGEN - Free Report) by 23.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,764,000 shares of the biopharmaceutical company's stock after pJune 6, 2024 | marketbeat.comFibroGen (NASDAQ:FGEN) Receives Market Perform Rating from William BlairWilliam Blair restated a "market perform" rating on shares of FibroGen in a research note on Monday.June 3, 2024 | marketbeat.comFibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical TrialsJune 3, 2024 | globenewswire.comFibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid TumorsJune 3, 2024 | globenewswire.comPamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial StrainsMay 28, 2024 | seekingalpha.com7 Penny Biotech Stocks to Triple Your InvestmentMay 28, 2024 | investorplace.comFibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual MeetingMay 23, 2024 | globenewswire.comAssenagon Asset Management S.A. Sells 1,798,009 Shares of FibroGen, Inc. (NASDAQ:FGEN)Assenagon Asset Management S.A. trimmed its position in shares of FibroGen, Inc. (NASDAQ:FGEN - Free Report) by 80.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 428,848 shares of the biopharmaceutical company'sMay 21, 2024 | marketbeat.comFibroGen, Inc. (NASDAQ:FGEN) to Post Q2 2024 Earnings of ($0.24) Per Share, William Blair ForecastsFibroGen, Inc. (NASDAQ:FGEN - Free Report) - Equities researchers at William Blair increased their Q2 2024 earnings estimates for shares of FibroGen in a research note issued on Tuesday, May 7th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will earn ($0.24) pMay 10, 2024 | marketbeat.comFibroGen, Inc. to Post Q1 2025 Earnings of $0.00 Per Share, William Blair Forecasts (NASDAQ:FGEN)FibroGen, Inc. (NASDAQ:FGEN - Free Report) - Research analysts at William Blair cut their Q1 2025 earnings estimates for shares of FibroGen in a note issued to investors on Tuesday, May 7th. William Blair analyst A. Hsieh now expects that the biopharmaceutical company will post earnings per shareMay 9, 2024 | marketbeat.comFibroGen First Quarter 2024 Earnings: Beats ExpectationsMay 8, 2024 | finance.yahoo.comFibroGen Shares Climb On Strong Q1 SalesMay 7, 2024 | msn.comFibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call TranscriptMay 7, 2024 | finance.yahoo.comGoldman Sachs Remains a Sell on FibroGen (FGEN)May 7, 2024 | markets.businessinsider.comFibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 7, 2024 | finance.yahoo.comFibroGen to Participate in Upcoming Investor ConferencesMay 7, 2024 | globenewswire.comFGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | msn.com Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. FGEN Media Mentions By Week FGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FGEN News Sentiment▼0.800.45▲Average Medical News Sentiment FGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FGEN Articles This Week▼62▲FGEN Articles Average Week Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Seres Therapeutics News Today Sagimet Biosciences News Today Puma Biotechnology News Today Incannex Healthcare News Today Skye Bioscience News Today Telomir Pharmaceuticals News Today Ventyx Biosciences News Today Repare Therapeutics News Today Context Therapeutics News Today InflaRx News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FGEN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
